Dyslipidemia is one of the leading causes of various cardiovascular and central nervous system disorders. Death from cardio-vascular disorders accounted for 36.3% of the 2.4 million deaths worldwide. Recognition that dyslipidemia is a risk factor has led to the development of drugs that modify cholesterol level. The intensity of therapy should be sufficient to achieve 30-40% reduction in LDL-C without side effects and low cost. The prescription order is an important therapeutic transaction between the prescriber and the patient. It has been well accepted that inadequate and irrational prescriptions could lead to serious consequences. The study was carried out by observing and analyzing data of 100 consecutive patients admitted in ICU and receiving lipid lowering agents for a period of eighteen months. From the study it is found that statins are the cornerstone of pharmacotherapy of dyslipidemias. At the same time the importance of dietary manipulations can't be ignored in management of dyslipidemias. Statins are relatively safe drugs however a few significant adverse reactions such as myalgia were also encountered during the course of the study.